FDA grants interchangeable status to biosimilar Cyltezo 

Listen
Text
  • Small
  • Medium
  • Large

FDA approved Cyltezo as the first interchangeable biosimilar to treat certain inflammatory diseases, the agency said Oct. 18. 

The FDA originally approved Cyltezo in 2017. Now, pharmacists can substitute it for AbbVie's Humira without needing a prescriber to change the prescription. 

Cyltezo, a tumor necrosis factor blocker, is approved to treat several diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and plaque psoriasis.

Cyltezo is the second interchangeable biosimilar product approved by the agency.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast